{
  "id": 12136778,
  "title": "Why is Vaxcyte stock surging today?",
  "url": "https://urgent.news/2026/10/05/why-is-vaxcyte-stock-surging-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-05T11:15:11.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-vaxcyte-stock-surging-today-93CH-4931775"
  },
  "original_language": "en",
  "account": "Vaxcyte stock experienced a remarkable 51.3% surge in pre-market trading following the release of positive topline data from its pivotal adult Phase 3 trial, OPUS-1, examining its VAX-31 vaccine candidate. The trial, which included 4,047 participants across around 30 U.S. sites, showcased VAX-31's successful performance in all co-primary immunogenicity endpoints. Every serotype shared with Pfizer's Prevnar 20 and Merck's Capvaxive met the noninferiority threshold, while the three unique serotypes of VAX-31 and cross-reactive serotype 20B demonstrated superiority. This strong data performance led to swift analyst enthusiasm, with Guggenheim raising its price target on PCVX to $125 from $116 while maintaining its Buy rating. The positive results also fueled a short squeeze dynamic, as the stock's short interest had been roughly 10% of the float, a level that typically intensifies upward moves when significant clinical events turn favorable. The broader market, however, remained relatively subdued, with the S&P 500, Dow Jones, and NASDAQ all modestly lower on the day, indicating that Vaxcyte's surge is primarily driven by company-specific news rather than macroeconomic factors. Industry peers Pfizer and Merck, whose vaccines were used as benchmarks in the OPUS-1 trial, now face a more competitive landscape. The company's upcoming Biologics License Application submission, scheduled for the first half of 2028, and anticipated results from OPUS-2 and OPUS-3 adult Phase 3 trials in the first half of 2027 further de-risk the path to commercialization for Vaxcyte.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Guggenheim raises Vaxcyte stock price target on vaccine trial win",
        "url": "https://urgent.news/2026/10/05/guggenheim-raises-vaxcyte-stock-price-target-on-vaccine-trial-win",
        "published": "2026-10-05T11:14:55.000Z"
      },
      {
        "outlet": "STAT News",
        "title": "STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market",
        "url": "https://urgent.news/2026/10/05/stat-vaxcyte-claims-success-in-bid-to-beat-pfizer-and-merck-in",
        "published": "2026-10-05T12:19:11.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}